» Articles » PMID: 28207639

Predictors of Waitlist Mortality in Portopulmonary Hypertension

Overview
Journal Transplantation
Specialty General Surgery
Date 2017 Feb 17
PMID 28207639
Citations 19
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The current Organ Procurement Transplantation Network policy grants Model for End-Stage Liver Disease (MELD) exception points to patients with portopulmonary hypertension (POPH), but potentially important factors, such as severity of liver disease and pulmonary hypertension, are not included in the exception score, and may affect survival. The purpose of this study was to identify significant predictors of waitlist mortality in patients with POPH.

Methods: We performed a retrospective cohort study of patients in the Organ Procurement and Transplantation Network database with hemodynamics consistent with POPH (defined as mean pulmonary arterial pressure >25 mm Hg and pulmonary vascular resistance [PVR] ≥240 dynes·s·cm) who were approved for a POPH MELD exception between 2006 and 2014. Using a Cox proportional hazards model, we identified predictors of waitlist mortality (or removal for clinical deterioration).

Results: One hundred ninety adults were included. Age (hazard ratio [HR], 1.04; 95% confidence interval [CI], 1.00-1.08; P = 0.0499), initial native MELD score (HR, 1.11; 95% CI, 1.05-1.17; P < 0.001), and initial PVR (HR, 1.12 per 100 dynes·s·cm; 95% CI, 1.02-1.23; P = 0.02) were the only significant univariate predictors of waitlist mortality and remained significant predictors in a multivariate model, which had a c-statistic of 0.71. PVR and mean pulmonary arterial pressure were not significant predictors of posttransplant mortality.

Conclusions: Both the severity of liver disease and POPH (as assessed by MELD and PVR, respectively) were significantly associated with waitlist, but not posttransplant, mortality in patients with approved MELD exceptions for POPH. Both factors should potentially be included in the POPH MELD exception score to more accurately reflect waitlist mortality risk.

Citing Articles

Portopulmonary hypertension: Current developments and future perspectives.

Xu H, Cheng B, Wang R, Ding M, Gao Y Liver Res. 2025; 6(1):10-20.

PMID: 39959808 PMC: 11791819. DOI: 10.1016/j.livres.2022.02.002.


The Clinical Course of Portopulmonary Hypertension and Outcomes With Endothelin Receptor Antagonist Treatment: Observational Study of Data From the US Organ Procurement and Transplantation Network.

DuBrock H, Jose A, Arendse S, Martin N, Studer S, Rosenberg D Transplant Direct. 2025; 10(3):e1586.

PMID: 39877650 PMC: 11774562. DOI: 10.1097/TXD.0000000000001586.


Clinical outcomes of upfront combination therapy for portopulmonary hypertension.

Kiko T, Asano R, Endo H, Nishi N, Hayashi H, Ueda J Int J Cardiol Cardiovasc Risk Prev. 2024; 22:200294.

PMID: 38872733 PMC: 11168483. DOI: 10.1016/j.ijcrp.2024.200294.


Association of Cardiopulmonary Hemodynamics and Mortality in Veterans With Liver Cirrhosis: A Retrospective Cohort Study.

Jose A, Rahman N, Opotowsky A, Glorioso T, Waldo S, Zeder K J Am Heart Assoc. 2024; 13(8):e033847.

PMID: 38567662 PMC: 11262483. DOI: 10.1161/JAHA.123.033847.


Asian Pacific Association for the Study of the Liver clinical practice guidelines on liver transplantation.

Kim D, Yoon Y, Kim B, Choudhury A, Kulkarni A, Park J Hepatol Int. 2024; 18(2):299-383.

PMID: 38416312 DOI: 10.1007/s12072-023-10629-3.


References
1.
Torregrosa M, Genesca J, Gonzalez A, Evangelista A, Mora A, Margarit C . Role of Doppler echocardiography in the assessment of portopulmonary hypertension in liver transplantation candidates. Transplantation. 2001; 71(4):572-4. DOI: 10.1097/00007890-200102270-00015. View

2.
Rodriguez-Roisin R, Krowka M, Herve P, Fallon M . Pulmonary-Hepatic vascular Disorders (PHD). Eur Respir J. 2004; 24(5):861-80. DOI: 10.1183/09031936.04.00010904. View

3.
Hoeper M, Bogaard H, Condliffe R, Frantz R, Khanna D, Kurzyna M . Definitions and diagnosis of pulmonary hypertension. J Am Coll Cardiol. 2013; 62(25 Suppl):D42-50. DOI: 10.1016/j.jacc.2013.10.032. View

4.
Colle I, Moreau R, Godinho E, Belghiti J, Ettori F, Cohen-Solal A . Diagnosis of portopulmonary hypertension in candidates for liver transplantation: a prospective study. Hepatology. 2003; 37(2):401-9. DOI: 10.1053/jhep.2003.50060. View

5.
Krowka M, Miller D, Barst R, Taichman D, Dweik R, Badesch D . Portopulmonary hypertension: a report from the US-based REVEAL Registry. Chest. 2011; 141(4):906-915. DOI: 10.1378/chest.11-0160. View